BridgeBio Pharma, Inc. (BBIO) FY2026 YTD Q3 P&L / Income Statement

Published · Updated Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

2026-01-01 to 2026-09-30

Revenue by Business Segment by Product and Service

Swipe to see the full flow
BridgeBio Pharma, Inc. (BBIO) FY2026 YTD Q3 P&L / Income StatementIncome statement for 2026-01-01 through 2026-09-30. View: Segments by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUEGROSSOPERATINGPRE-TAXNETReportable Segment - Net product revenueReportable Segment - License and services revenueReportable Segment - Royalty revenueTotal revenues, netGross profit (calculated)Total cost of revenuesLoss from operationsOperating expenses (calculated)Selling, general and administrativeResearch and developmentLoss before income taxesTotal other expense, netNet lossProvision for (benefit from) income taxesGross profit (calculated)Gross profit(calculated)$745.93 MLoss before income taxesLoss beforeincome taxes−$381.71 MTotal revenues, netTotal revenues, net$791.36 MLoss from operationsLoss from operations−$224.67 MNet lossNet loss−$382.94 MReportable Segment - Net product revenueReportable Segment -Net product revenue$656.38 MOperating expenses (calculated)Operating expenses(calculated)$970.60 MProvision for (benefit from) income taxesProvision for (benefitfrom) income taxes$1.23 MSelling, general and administrativeSelling, general and administrative$551.01 MReportable Segment - License and services revenueReportable Segment - Licenseand services revenue$89.54 MTotal cost of revenuesTotal cost of revenues$45.44 MReportable Segment - Royalty revenueReportable Segment - Royalty revenue$45.44 MResearch and developmentResearch and development$419.59 MTotal other expense, netTotal otherexpense, net−$157.04 M
Chart details

BridgeBio Pharma, Inc. (BBIO) FY2026 YTD Q3 P&L / Income Statement

Income statement for 2026-01-01 through 2026-09-30. View: Segments by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues, net
791,362,000 US dollars
Total cost of revenues
45,435,000 US dollars
Gross profit (calculated)
745,927,000 US dollars
Operating expenses (calculated)
970,601,000 US dollars
Loss from operations
negative 224,674,000 US dollars
Total other expense, net
negative 157,039,000 US dollars
Loss before income taxes
negative 381,713,000 US dollars
Provision for (benefit from) income taxes
1,229,000 US dollars
Net loss
negative 382,942,000 US dollars
Reportable Segment - License and services revenue
89,537,000 US dollars
Reportable Segment - Net product revenue
656,382,000 US dollars
Reportable Segment - Royalty revenue
45,443,000 US dollars
Restructuring, impairment, and related charges
0 US dollars
Research and development
419,590,000 US dollars
Selling, general and administrative
551,011,000 US dollars

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
  • Of which attributable to BridgeBio Pharma, Inc.: −$372.97 M; to noncontrolling interests: −$9.97 M.
BridgeBio Pharma, Inc. (BBIO) FY2026 YTD Q3 Revenue by Business Segment by Product and Service Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!